Please ensure Javascript is enabled for purposes of website accessibility

Is Moderna a Long-Term Buy?

By Adria Cimino - Jan 29, 2021 at 8:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This may not be a one-product company for long.

Investors flocked to Moderna (MRNA 8.73%) last year with hopes its coronavirus vaccine program would bear fruit. Since, the company has become one of the first to commercialize a coronavirus vaccine. But Moderna's growth story isn't over. In this Motley Fool Live video recorded on Jan. 22, 2021, healthcare and cannabis bureau chief Corinne Cardina and contributor Adria Cimino discuss the elements that could push Moderna shares higher over the long term.

Corinne Cardina: What about Moderna? Do you think the stock is overvalued or given its extensive pipeline and proof-of-concept having been achieved with mRNA, could it be a good long-term buy at today's prices?

Adria Cimino: I definitely think it's a good long-term buy at today's price. I think the proof-of-concept with mRNA, that's really big. First of all, we have this year the idea that all of a sudden this company that was before clinical stage is now going to produce revenue in the billions. That's pretty significant. Beyond that, it recently announced three new infectious disease programs. They are going to work on preventative vaccines for HIV, seasonal flu, and Nipah virus. Now for the flu and for HIV, they're starting phase 1. They aim to start phase 1 this year. This is really significant, the idea that we're not just talking about one product anymore, but now there's technology that we see works in humans. Well, that is a pretty good indication that it could work for some of these other indications as well like HIV, seasonal flu. I definitely think there is room for long-term growth with Moderna.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$147.66 (8.73%) $11.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.